Eli Lilly (LLY) Stock Climbs Following $3.83 Billion Vaccine Company Acquisitions

TLDR

• Eli Lilly revealed agreements to purchase three vaccine development companies — Curevo, LimmaTech Biologics, and the Vaccine Company — in deals worth approximately $3.83 billion combined.
• The Curevo acquisition carries a potential value of up to $1.5 billion and centers on an adult shingles vaccine candidate.
• LimmaTech’s acquisition, valued at up to $780 million, targets bacterial pathogen vaccines including those for sexually transmitted infections.
• The Vaccine Company deal, worth up to $1.55 billion, focuses on developing an Epstein-Barr virus vaccine.
• Shares of LLY climbed approximately 1.3%–1.6% during premarket trading following the announcement.

Eli Lilly is deploying nearly $4 billion in capital to establish a foothold in infectious disease prevention. On Tuesday, the pharmaceutical company revealed it has reached agreements to purchase three biotech companies: Curevo, LimmaTech Biologics, and the Vaccine Company.

Eli Lilly and Company, LLY

Shares of LLY gained between 1.3% and 1.6% in premarket activity following the announcement.

Each acquisition is structured with initial payments alongside potential future milestone-based payments linked to regulatory and commercial achievements. The three transactions collectively represent approximately $3.83 billion in total potential value.

Curevo represents the most substantial transaction at a potential $1.5 billion. The biotech has engineered a shingles vaccine utilizing a synthetic adjuvant — intended to enhance immune system activation while minimizing adverse reactions relative to currently available treatments.

The Vaccine Company acquisition follows closely with a valuation reaching $1.55 billion. The company utilizes In Vivo Nanoparticle technology to combat viral pathogens, with primary emphasis on the Epstein-Barr virus — a widespread infection lacking any approved preventive vaccine.

LimmaTech completes the acquisition trio with a value of up to $780 million. The company’s development pipeline addresses bacterial pathogens, including Neisseria gonorrhoeae and chlamydia trachomatis — organisms where antibiotic resistance presents an escalating medical challenge.

Funded by GLP-1 Success

Lilly’s purchasing strategy is financed through extraordinary commercial performance of its metabolic disease therapies. During the first quarter, Zepbound generated $4.16 billion in U.S. revenue, while Mounjaro contributed $4.2 billion.

This financial strength has positioned Lilly to diversify significantly beyond its weight management portfolio. The three vaccine acquisitions represent a continuation of Lilly’s strategy to allocate resources into emerging therapeutic categories while expanding its development pipeline.

The pharmaceutical company currently commands a 60.1% market share in the U.S. obesity medication sector, with competitor Novo Nordisk holding 39.4%. Lilly also introduced Foundayo, its recently approved oral GLP-1 obesity medication, during the second quarter.

Three Vaccines, Three Gaps in the Market

Each acquisition addresses a specific unmet medical need where effective vaccines are either unavailable or require enhancement.

Shingles impacts approximately one in three Americans during their lifetime. The Epstein-Barr virus has infected roughly 90% of the adult population worldwide and has been associated with specific malignancies and multiple sclerosis. Bacterial sexually transmitted infections such as gonorrhea increasingly demonstrate resistance to available antibiotic therapies.

Lilly has not revealed the precise upfront payment figures for any transaction, disclosing only the aggregate potential valuations including milestone payments.

The Wall Street Journal initially reported the transactions Tuesday morning prior to Lilly’s formal disclosure.

The post Eli Lilly (LLY) Stock Climbs Following $3.83 Billion Vaccine Company Acquisitions appeared first on Blockonomi.